High dose intravenous immunoglobulin may be complicated by myocardial infarction

Indian Journal of Critical Care Medicine

Volumn 18, Issue 4, 2014, Pages 247-249

  Vinod, Kolar Vishwanath ^a   Kumar, Mritunjai ^a   Nisar, Kare Kadavath ^a  

^a JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Adverse events; intravenous immunoglobulin; myocardial infarction; thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; DOBUTAMINE; DOPAMINE; ENALAPRIL; ENOXAPARIN; IMMUNOGLOBULIN; MALTOSE; METOPROLOL; NORADRENALIN; NORGLOBIN; STREPTOKINASE; TROPONIN T; UNCLASSIFIED DRUG;

AGED; ANTERIOR MYOCARDIAL INFARCTION; ARTICLE; ARTIFICIAL VENTILATION; AUTONOMIC DYSFUNCTION; BREATHING MUSCLE; CASE REPORT; CHEMOPROPHYLAXIS; CRANIAL NERVE PARALYSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG RESPONSE; DRUG SAFETY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; ENDOTRACHEAL INTUBATION; FIBRINOLYTIC THERAPY; GUILLAIN BARRE SYNDROME; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HUMAN; HYPERTENSION; HYPOKINESIA; HYPOTENSION; IMMUNOTHERAPY; INTENSIVE CARE; IRON DEFICIENCY ANEMIA; LIMB WEAKNESS; MALE; NECK MUSCLE; NOSE FEEDING; PARALYSIS; QUADRIPLEGIA; RESTLESSNESS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SWEATING; SYMMETRIC AREFLEXIC QUADRIPARESIS; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; VEIN THROMBOSIS;

EID: 84898830804     PISSN: 09725229     EISSN: 1998359X     Source Type: Journal    
DOI: 10.4103/0972-5229.130579     Document Type: Article

References (10)

1. Tufan F, Kamali S, Erer B, Gul A, Inanc M, Ocal L, et al. Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseases. Clin Rheumatol 2007;26:1913-5.
2. Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmun Rev 2007;6:257-9.
3. Paran D, Herishanu Y, Elkayam O, Shopin L, Ben-Ami R. Venous and arterial thrombosis following administration of intravenous immunoglobulins. Blood Coagul Fibrinolysis 2005;16:313-8.
4. Caress JB, Hobson-Webb L, Passmore LV, Finkbiner AP, Cartwright MS. Case-control study of thromboembolic events associated with IV immunoglobulin. J Neurol 2009;256:339-42.
5. Mukerji S, Aloka F, Farooq MU, Kassab MY, Abela GS. Cardiovascular complications of the Guillain-Barré syndrome. Am J Cardiol 2009;104:1452-5.
6. Elkayam O, Paran D, Milo R, Davidovitz Y, Almoznino-Sarafian D, Zeltser D, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders: A study of four cases. Ann Rheum Dis 2000;59:77-80.
7. Marie I, Maurey G, Hervé F, Hellot MF, Levesque H. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature. Br J Dermatol 2006;155:714-21.
8. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: A case report and discussion of the relevant literature. Ann Hematol 2004;83:661-5.
9. Vo AA, Cam V, Toyoda M, Puliyanda DP, Lukovsky M, Bunnapradist S, et al. Safety and adverse events profiles of intravenous gammaglobulin products used for immunomodulation: A single-center experience. Clin J Am Soc Nephrol 2006;1:844-52.
10. Huang L, Kanellis J, Mulley W. Slow and steady. Reducing thrombotic events in renal transplant recipients treated with IVIg for antibody-mediated rejection. Nephrology (Carlton) 2011;16:239-42.